As reported by pharmaphorum last month, Novartis’ Arzerra, a repurposed cancer drug formerly owned by GlaxoSmithKline, outperformed Aubagio in a phase 3 trial last month. Celgene’s ozanimod is ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

TG Therapeutics stock rose Wednesday after the biotech company said 92% of patients who took its multiple sclerosis drug, Briumvi ... treatment with Sanofi's Aubagio and then switched to Briumvi ...

failed to show significance in the primary endpoint of reducing an annualized relapse rate over another Sanofi MS drug, Aubagio. However, when a key secondary endpoint of pooled 6-month confirmed ...